YOLFTbeta
Hyundai Pharm

Hyundai Pharm

004310 · KO · Healthcare / Drug Manufacturers - Specialty & Generic

6,510.00KRW+10.00 (+0.15%)

Price History

Full chart

Market Stats

Previous Close6,500.00
Open6,500.00
Day Range6,470.00 – 6,770.00
52-Week Range3,490.28 – 15,915.67
Volume390.26K
Market Cap260.32B
P/E (TTM)0.00
Forward P/E0.00
Dividend Yield0.35%
Beta0.72
50-Day Avg7,417.20
200-Day Avg8,439.00

About

Hyundai Pharmaceutical Co., Ltd. manufactures and distributes pharmaceutical products, health food drinks, and medical devices in South Korea and internationally. The company offers a range of ETC and OTC products in various therapeutic areas, including antianginal, antibiotic, antiemetics+antinauseants, antihistamines and antiallergics, antihyperlipidemic, antihypertensive, antiplatelet agent, antitussives, cell stimulants and proliferants, central nervous system, depilatory, dermatological agent, dermatology, dietary supplements, digestive system, endocrine system, expectorants, eye tonic and vitamins, gynaecolog antifungals, gynaecologic antiseptics, hemostatics, labour inhibitors, leukotriene modulator, narcotic analgesics, NSAIDs, oestrogens, ophthalmic products, OTH.sex horm and similar, SERMS, systemic hormonal contraceptives, urogenital system depilatory, uterotonic products, various alimentary tract and metabolism products, vitamins, acne, allergy, alopecia treatment, analgesics and anti-inflammatory, anemia, antimicrobial and antivirus, arthritis, contraceptives, dermatological agent, diagnostic reagent, gastrointestinal disorder and digestant, lip care, nutrition, ophthalmic product, respiratory, urogenital system, wound healing, and others. Hyundai Pharmaceutical Co., Ltd. was founded in 1965 and is headquartered in Seoul, South Korea.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEOSang-Jun Lee
  • Employees0
  • HeadquartersHyundai Pharm Building, Seoul, South Korea, 06121, Korea
  • Websitehttps://www.hyundaipharm.co.kr

Leadership

  • Sang-Jun LeePresident · b. 1976

Financials

Income Statement

Currency: KRW2010-11-302011-11-302012-11-302013-11-302016-11-302017-11-302018-11-302019-11-302020-11-302021-11-302022-11-302023-11-302024-11-302025-11-30
Total Revenue111.86B114.28B102.25B108.14B120.02B130.48B133.94B134.92B132.97B139.80B162.69B180.76B175.74B191.79B
Growth (%)-+2.16%-10.52%+5.75%+10.99%+8.71%+2.65%+0.73%-1.45%+5.14%+16.37%+11.11%-2.78%+9.14%
Cost of Revenue66.33B68.59B63.18B67.64B72.88B68.50B70.31B71.06B74.64B83.49B93.85B104.17B102.37B112.19B
Gross Profit45.53B45.68B39.07B40.49B47.14B61.98B63.64B63.86B58.32B56.31B68.84B76.59B73.37B79.60B
Gross Margin40.70%39.98%38.21%37.44%39.27%47.50%47.51%47.33%43.86%40.28%42.31%42.37%41.75%41.51%
Operating Expense46.41B42.22B43.39B38.30B44.81B59.97B62.41B62.30B55.27B57.88B60.87B69.67B73.18B75.44B
Operating Income-882.80M3.46B-4.32B2.19B2.33B2.01B1.22B1.56B3.05B-1.57B7.97B6.93B180.89M4.16B
Operating Margin-0.79%3.03%-4.22%2.02%1.94%1.54%0.91%1.16%2.30%-1.12%4.90%3.83%0.10%2.17%
EBITDA-----4.94B796.86M5.71B7.41B670.96M10.13B13.24B3.94B8.47B
EBITDA Margin-----3.79%0.59%4.24%5.57%0.48%6.23%7.33%2.24%4.42%
Net Income2.97B520.10M-4.85B1.41B1.26B1.46B928.94M1.16B2.19B-3.17B-164.58M6.12B-574.89M2.52B
Net Income Margin2.65%0.46%-4.74%1.31%1.05%1.12%0.69%0.86%1.64%-2.27%-0.10%3.39%-0.33%1.31%
R&D659.63M165.40M391.59M67.69M6.00M13.13B13.49B12.47B9.62B8.09B8.38B12.23B15.33B17.71B
R&D as % of Total Revenue0.59%0.14%0.38%0.06%0.00%10.06%10.07%9.24%7.24%5.79%5.15%6.77%8.72%9.23%
Interest Expense000000727.20M678.28M614.07M712.77M1.16B1.91B1.99B1.89B
Interest Expense % of Total Revenue0.00%0.00%0.00%0.00%0.00%0.00%0.54%0.50%0.46%0.51%0.71%1.06%1.13%0.98%

Balance Sheet

Currency: KRW2010-11-302011-11-302012-11-302013-11-302016-11-302017-11-302018-11-302019-11-302020-11-302021-11-302022-11-302023-11-302024-11-302025-11-30
Total Assets130.98B156.95B149.90B143.40B150.55B154.62B158.80B145.47B157.50B163.86B181.16B154.63B156.40B163.22B
Total Liabilities38.48B52.63B50.22B42.19B50.47B56.52B51.80B57.89B67.36B77.26B94.60B69.97B77.32B81.11B
Total Equity92.50B103.86B99.22B100.71B100.08B98.10B107.00B87.58B90.14B86.60B86.56B84.66B79.07B82.10B
Cash11.32B13.63B16.27B14.09B8.62B8.23B7.36B7.40B13.27B21.63B30.27B16.20B10.28B2.50B
Net Debt-----21.22B13.64B13.60B10.73B7.37B8.73B21.80B37.34B47.03B

Cash Flow

Currency: KRW1999-11-302000-11-302001-11-302010-11-302011-11-302012-11-302013-11-302016-11-302017-11-302018-11-302019-11-302020-11-302021-11-302022-11-302023-11-302024-11-302025-11-30
Operating Cash Flow---2.68B6.27B-2.70B7.95B-2.75B-1.98B2.83B6.96B10.80B5.13B11.62B-4.55B-2.37B-123.29M
Investing Cash Flow---5.91B-2.93B4.81B-713.02M----------
Financing Cash Flow----4.80B-1.37B528.39M-9.42B----------
Capital Expenditure0003.95B3.68B1.46B2.24B3.68B3.10B2.67B2.36B6.40B6.81B6.58B6.10B11.18B5.86B
Free Cash Flow---------5.08B168.09M3.35B4.40B-1.68B5.04B-10.65B-13.56B-5.99B
Dividends Paid---1.22B1.06B938.61M881.70M1.16B1.15B1.18B1.23B1.21B1.18B836.05M826.20M923.13M783.72M
FCF to OCF--------256.62%5.93%48.19%40.76%-32.67%43.36%234.30%571.24%4856.98%
Dividend Paid to FCF---------22.53%701.71%36.73%27.58%-70.64%16.59%-7.76%-6.81%-13.09%

Earnings

Report DateNov 30, 2010Feb 28, 2011May 31, 2011Aug 31, 2011Feb 29, 2012Jul 13, 2012Oct 15, 2012Feb 28, 2013Apr 15, 2013Jul 15, 2013Oct 15, 2013Nov 30, 2013Feb 28, 2014May 31, 2014Aug 31, 2014Nov 30, 2014Feb 28, 2015May 31, 2015Aug 31, 2015Nov 30, 2015Feb 29, 2016May 31, 2016Aug 31, 2016Nov 30, 2016Feb 28, 2017May 31, 2017Aug 31, 2017Nov 30, 2017Feb 28, 2018May 31, 2018Aug 31, 2018Nov 30, 2018Feb 28, 2019May 31, 2019Aug 31, 2019Nov 30, 2019Feb 29, 2020May 31, 2020Aug 31, 2020Nov 30, 2020Feb 28, 2021May 31, 2021Aug 31, 2021Nov 30, 2021Feb 28, 2022May 31, 2022Aug 31, 2022Nov 30, 2022Feb 28, 2023May 31, 2023Aug 31, 2023Feb 23, 2024Feb 29, 2024May 31, 2024Aug 31, 2024Nov 30, 2024Feb 28, 2025May 31, 2025Aug 31, 2025Nov 30, 2025Feb 28, 2026May 31, 2026
EPS Estimate--------------------------------------------------------------
EPS Actual-22.4360.78-10.55-32.0410.14-143.54-46.51-21.7519.7925.3822.00-8.4011.7116.4314.1118.7310.5122.1810.2722.3914.0018.869.907.5914.9319.8111.7413.7214.9617.3210.77-120.7915.9322.088.21-3.855.33108.34-34.001.71-34.5615.64-8.24-86.6742.1186.2886.78-221.0860.79114.9964.94-16.1611.6441.25-18.65-56.57-37.7036.6097.3510.2616.0339.20
Surprise--------------------------------------------------------------
Timing-----Pre-marketPre-marketAfter-hoursPre-marketPre-marketPre-market----------------------------------------Pre-market----------

Key Statistics & Ratios

Market Cap260.32B
Enterprise Value304.85B
Trailing P/E0.00
Forward P/E0.00
PEG Ratio0.00
Price / Sales2.41
Price / Book2.14
Revenue (TTM)108.14B
Gross Profit (TTM)40.49B
EBITDA4.30B
Profit Margin1.31%
Operating Margin1.65%
Return on Equity1.45%
Return on Assets0.93%
Shares Outstanding30.92M
Shares Float14.91M
Beta0.72
Dividend Yield0.35%
Dividend Rate30.00
Payout Ratio45.81%

Dividends

20261×
30.00Mar 3, 2026
20251×
30.00Mar 4, 2025
20241×
35.00Mar 5, 2024
20222×
41299.20Dec 28, 202230.00Nov 29, 2022
20212×
41299.20Dec 29, 202130.00Nov 29, 2021
20201×
42.50Nov 27, 2020
20191×
45.00Nov 28, 2019
20181×
45.00Nov 29, 2018
20171×
50.00Nov 29, 2017
20161×
46.27Nov 29, 2016
20151×
46.27Nov 27, 2015
20141×
43.84Nov 27, 2014
20131×
41.40Nov 28, 2013
20121×
36.53Nov 29, 2012
20111×
38.96Nov 29, 2011
20101×
43.84Nov 29, 2010
20091×
48.71Nov 27, 2009
20081×
63.32Nov 27, 2008
20071×
73.06Nov 28, 2007
20061×
73.06Nov 29, 2006
20051×
68.19Nov 29, 2005
20041×
63.32Nov 29, 2004

Stock Splits

  • Mar 17, 200810:1